3 Dividend ETFs Crushing the S&P 500 in 2026
The S&P 500 ($SPX) is up about 14% year-to-date. Using TipRanks’ ETF Comparison tool, we identified three dividend ETFs, the iShares Core High Divi...
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 9,497,970 | $2,390,069,445 | +5% | 0.71% |
| 2. | Citadel Investment Group Ken Griffin | 3,169,783 | $797,644,194 | +547% | 0.09% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,990,512 | $752,532,440 | +281758% | 0.59% |
| 4. | D E Shaw D. E. Shaw | 2,102,316 | $529,026,798 | +213% | 0.25% |
| 5. | AQR Capital Management Cliff Asness | 2,015,238 | $507,114,594 | +127% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $250.00 | 32,710 | $8,177,500.00 | 74,430 | 2026-08-14 | Filing | |
| $233.56 | 5,230 | $1,221,518.80 | 2,654 | 2026-03-04 | Filing | |
| $235.26 | 2,600 | $611,676.00 | 4,619 | 2026-03-02 | Filing | |
| $234.66 | 10,291 | $2,414,886.06 | 7,219 | 2026-03-02 | Filing | |
| $233.51 | 5,777 | $1,348,987.27 | 17,510 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 149,488,412 | $37,617,263,993 | 0.56% | |
| 2. | 115,396,098 | $29,038,274,101 | 0.62% | |
| 3. | 82,596,748 | $20,784,645,667 | 0.62% | |
| 4. | 48,477,996 | $12,199,002,913 | 0.55% | |
| 5. | 47,862,796 | $12,171,988,269 | 0.67% |
News See All
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20).
Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?
The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050.
Could AbbVie Inc. (ABBV)'s Post-Humira Transformation Drive the Next Phase of Growth?
AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally).
AbbVie's (ABBV) Botox Just Got A Step Closer To A Fifth Use
AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands.
Options Volatility and Implied Earnings Moves Today, July 31, 2026
Today, several major companies are expected to report earnings: Cameco (CCJ), Chevron (CVX), Colgate-Palmolive (CL), Dominion Energy (D), Eaton (ET...
10 Best Dividend Aristocrat Stocks To Buy Now
Global equity markets are on edge amid uncertainty in the Middle East, compounded by economic growth concerns.
10 Best July Dividend Stocks to Buy
Dividend stocks have remained a popular choice for investors over the years. They offer the potential for long-term returns while providing a steady stream of income.
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc.
12 Most Profitable S&P 500 Stocks to Invest In
Profitability is being watched more closely as investors look beyond headline earnings and ask how efficiently companies turn shareholder capital into profits.
Hedge Fund Resource Center